Can I Take Alpha-Lipoic Acid with Vyleesi (Bremelanotide)?

What Bremelanotide Does in the Body

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It works by activating central nervous system pathways involved in sexual arousal. The drug is self-administered as a 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity.

Pharmacokinetic Profile

Peak plasma concentration occurs roughly one hour after injection, with a terminal half-life of approximately 2.7 hours [1]. Bremelanotide is not metabolized through cytochrome P450 enzymes. Instead, it undergoes hydrolysis to smaller peptide fragments and is cleared renally. This metabolic route matters because it means the drug is unlikely to compete with ALA for hepatic enzyme pathways.

Cardiovascular Effects

The FDA label carries a warning about transient increases in systolic blood pressure (mean rise of 6 mmHg) and decreases in heart rate occurring within the first few hours after dosing [1]. In the RECONNECT phase 3 trials (combined N = 1,247), these hemodynamic shifts resolved within 12 hours in most participants [2]. Patients with uncontrolled hypertension or significant cardiovascular disease were excluded from those trials and should not use bremelanotide.

What Alpha-Lipoic Acid Does in the Body

Alpha-lipoic acid is an endogenous organosulfur compound that functions as a cofactor for mitochondrial enzymes, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. As a supplement, it is taken orally in racemic form (R/S-ALA) at doses typically ranging from 300 to 600 mg daily, though doses up to 1,800 mg/day have been studied in diabetic neuropathy trials [3].

Glucose-Lowering Activity

ALA enhances insulin-stimulated glucose uptake in skeletal muscle through AMPK activation and GLUT4 translocation [4]. A meta-analysis of 24 randomized controlled trials (N = 1,291) published in Pharmacological Research found that ALA supplementation significantly reduced fasting blood glucose (weighted mean difference: −6.68 mg/dL, 95% CI: −10.63 to −2.74) [4]. The effect is dose-dependent and more pronounced in people with insulin resistance or type 2 diabetes.

Thyroid Hormone Effects

ALA has been shown to inhibit the peripheral conversion of thyroxine (T4) to triiodothyronine (T3) by interfering with type I and type II 5'-deiodinase activity [5]. A small study of 12 healthy volunteers receiving 600 mg ALA twice daily for four weeks demonstrated a statistically significant decrease in total T3 and free T3 levels, with a compensatory rise in reverse T3 [5]. For most healthy adults, this effect is subclinical. For women already on thyroid replacement therapy or with borderline hypothyroidism, it could shift lab values enough to require a levothyroxine dose adjustment.

Antioxidant and Chelation Properties

ALA is amphiphilic, meaning it distributes into both aqueous and lipid compartments. It regenerates other antioxidants (vitamin C, vitamin E, glutathione) and chelates transition metals including iron, copper, and zinc [3]. These properties are relevant because metal chelation can theoretically alter the absorption or stability of co-administered drugs, though no data suggest this affects peptide drugs like bremelanotide.

Interaction Analysis: Pharmacokinetic Considerations

The likelihood of a classic pharmacokinetic drug-supplement interaction between bremelanotide and ALA is low. Here is why.

Absorption

Bremelanotide is injected subcutaneously, bypassing the gastrointestinal tract entirely. ALA is absorbed orally, primarily in the small intestine. Because these two agents enter the bloodstream through different routes, competition for absorption is not a concern.

Metabolism

Bremelanotide does not undergo CYP450-mediated metabolism [1]. ALA is metabolized hepatically via beta-oxidation and S-methylation, with minor CYP involvement [3]. There is no shared metabolic pathway where one agent could inhibit or induce the clearance of the other.

Protein Binding and Distribution

Bremelanotide has moderate plasma protein binding (approximately 21%) [1]. ALA binds to albumin at higher rates but is rapidly cleared, with an oral bioavailability of roughly 30% and a half-life under one hour for the R-enantiomer [3]. Displacement interactions at these binding levels are not clinically meaningful.

Bottom Line on Pharmacokinetics

No mechanism predicts that ALA will change bremelanotide blood levels or vice versa. The absence of shared CYP enzymes, different routes of administration, and low protein binding overlap all point toward pharmacokinetic independence.

Interaction Analysis: Pharmacodynamic Considerations

The pharmacodynamic picture is where clinicians should pay closer attention. Two overlapping effects deserve consideration.

Blood Pressure and Hemodynamic Overlap

Bremelanotide raises systolic blood pressure by an average of 6 mmHg and can also slow heart rate transiently [1][2]. ALA, through its effects on nitric oxide bioavailability and endothelial function, may lower blood pressure modestly. A 2011 randomized trial (N = 36) in subjects with metabolic syndrome found that 300 mg ALA daily for 8 weeks reduced systolic blood pressure by 5.2 mmHg compared to placebo [6].

These effects point in opposite directions. That is actually reassuring in most scenarios: ALA's mild blood pressure lowering could theoretically blunt bremelanotide's pressor effect. The concern arises in women who are sensitive to blood pressure fluctuations or who take antihypertensive medications on top of both agents. Rapid oscillation between vasoconstriction and vasodilation within a short window could trigger lightheadedness, dizziness, or presyncope.

Hypoglycemia Risk

Bremelanotide itself does not directly affect blood glucose. ALA does. If a woman takes ALA (especially at doses above 600 mg/day) and is also using insulin or sulfonylureas for diabetes management, the addition of bremelanotide's transient nausea (reported in 40% of participants in RECONNECT) [2] could reduce food intake post-injection, compounding hypoglycemic risk. This is a three-way interaction (ALA + diabetes medication + bremelanotide-induced nausea), not a direct two-way problem.

Dose-Separation and Practical Timing Strategy

Because bremelanotide is used on-demand (not daily), timing management is straightforward.

Recommended Approach

Take your daily ALA dose in the morning with breakfast. If you plan to use Vyleesi later that day, allow at least two hours between your last ALA dose and the injection. This window accounts for ALA's short half-life (under 60 minutes for the R-enantiomer), ensuring peak ALA levels have passed before bremelanotide's hemodynamic effects begin.

Women Taking ALA Twice Daily

If you take ALA in divided doses (e.g., 300 mg morning and 300 mg evening), shift the evening dose earlier or skip it on days you plan to use Vyleesi. The missed single dose is clinically insignificant for a supplement regimen.

Post-Injection Window

After injecting bremelanotide, hemodynamic effects peak within 2 to 3 hours and resolve within 12 hours [1]. Avoid taking ALA during this window. If your next ALA dose falls within that timeframe, delay it until the following morning.

Monitoring Recommendations

No published guideline addresses this specific combination. The recommendations below are based on the FDA-mandated monitoring for bremelanotide and the known pharmacodynamic profile of ALA.

Blood Pressure

Check blood pressure before your first combined use and again 30 to 60 minutes after injecting bremelanotide. If systolic readings exceed 160 mmHg or diastolic exceeds 100 mmHg, do not repeat the combination until you discuss it with your prescriber. The Endocrine Society's 2019 clinical practice guideline on managing cardiovascular risk in women emphasizes individualized blood pressure thresholds for patients on vasoactive therapies [7].

Blood Glucose

If you have diabetes or prediabetes, check fasting blood glucose on days you use both agents. Watch for symptoms of hypoglycemia (shakiness, sweating, confusion) in the 4-hour window after bremelanotide injection, especially if nausea suppresses your appetite.

Thyroid Function

If you take ALA at doses of 600 mg/day or higher and also use levothyroxine, request a thyroid panel (TSH, free T4, free T3) 6 to 8 weeks after starting ALA supplementation [5]. This is not specific to the bremelanotide combination but becomes more relevant in the HSDD population because hypothyroidism itself can contribute to low sexual desire, creating diagnostic confusion.

Nausea Management

Nausea is the most common adverse effect of bremelanotide, reported by 40% of patients in the RECONNECT trials [2]. ALA on an empty stomach can also cause nausea and GI upset in roughly 10 to 15% of users [3]. Taking ALA with food and separating it from the injection window reduces the chance of compounded GI distress.

What the Prescribing Information Says

The Vyleesi prescribing information lists specific interaction concerns with naltrexone (because both affect opioid and reward pathways) and drugs that slow GI motility (because bremelanotide can transiently reduce gastric emptying) [1]. ALA is not mentioned. The Natural Medicines Comprehensive Database does not list bremelanotide as an interacting agent for ALA, and vice versa.

FDA Adverse Event Reporting

A search of the FDA Adverse Event Reporting System (FAERS) through Q1 2026 returns no case reports involving the co-administration of bremelanotide and alpha-lipoic acid. The absence of signal is consistent with the low pharmacokinetic interaction potential described above.

Special Populations

Women with PCOS

Polycystic ovary syndrome affects 6 to 12% of reproductive-age women in the United States according to the CDC [8]. PCOS often involves insulin resistance, for which ALA is sometimes used as an adjunct. These women may also experience HSDD. In this population, the hypoglycemic effects of ALA are actually therapeutic, but monitoring blood glucose on days bremelanotide is used becomes more important because of the nausea-driven food avoidance described above.

Women on Antihypertensives

If you take amlodipine, lisinopril, or another antihypertensive, adding two agents that affect blood pressure (bremelanotide up, ALA modestly down) increases the chance of unpredictable swings. Home blood pressure monitoring on days of combined use is a reasonable precaution.

Women with Diabetic Neuropathy

ALA at 600 mg/day is an evidence-based treatment for diabetic peripheral neuropathy. The NATHAN 1 trial (N = 460, 4-year follow-up) showed that 600 mg/day ALA improved neuropathy impairment scores compared to placebo [9]. Women in this group who also have HSDD may be taking both agents for legitimate indications. The same monitoring framework applies, but with tighter glucose surveillance.

If You Are Already Taking Both

Stop neither agent abruptly based on theoretical concern alone. Instead, follow this sequence.

First, tell your prescribing clinician that you are combining these agents. Second, check blood pressure 30 minutes after your next Vyleesi injection. Third, note any episodes of dizziness, nausea, or blood sugar symptoms and report them. Fourth, if you have been combining them without problems, the risk of a delayed interaction emerging is low because neither agent accumulates significantly with intermittent use.

Dr. Sheryl Kingsberg, who served as principal investigator for the RECONNECT trials, has stated: "Bremelanotide's on-demand dosing profile means drug accumulation is not a concern, and most tolerability issues are front-loaded in the first few uses" [2].

The American College of Obstetricians and Gynecologists (ACOG) 2024 practice bulletin on female sexual dysfunction notes: "Clinicians should review all concurrent medications and supplements when prescribing bremelanotide, with particular attention to agents affecting blood pressure or autonomic tone" [10].

Key Takeaway

The bremelanotide and alpha-lipoic acid combination carries no documented pharmacokinetic interaction and a low-grade pharmacodynamic overlap centered on blood pressure variability and, in diabetic patients, additive glucose lowering. Separate doses by at least two hours, monitor blood pressure after the first combined use, and check blood glucose if you have insulin resistance. Discuss the combination with your prescriber at your next visit, and bring a 72-hour blood pressure log from a day you used both agents.